Jennifer A. Perry
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
111
Citations
5,080
Est. group size
~2
Recurring co-author estimate
Active years
53
Publishing since 1974
Jennifer A. Perry's work focuses on the molecular biology of acute myeloid leukemia (AML), particularly how genetic rearrangements involving KMT2A, NPM1, and MECOM drive blood cancers and how these can be targeted with drugs such as menin inhibitors. The research combines laboratory experiments (including CRISPR-based screening) with preclinical drug testing to identify and improve therapies for high-risk leukemia subtypes. Note that some listed titles (e.g., on ACL injury and hip biomechanics) appear unrelated to this leukemia research and may reflect a different individual sharing the same name.
Publication output was modest and variable from 2017–2022, spiked sharply in 2023, then returned to a lower, steady level through 2024–2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia
Leukemia · 2026
- Combining menin and MEK inhibition to target poor prognosis <i>KMT2A</i> -rearranged RAS pathway–mutant acute myeloid leukemia
Blood Advances · 2026
- CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials
Nature Communications · 2026
- CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias
Blood · 2025
- Single-leg Landing Coordination Variability and Second Injury in Young Athletes after Primary Anterior Cruciate Ligament Reconstruction
Medicine & Science in Sports & Exercise · 2025
- The KMT2A-PTD oncoprotein depends on ENL but not menin to drive AML gene expression
Blood · 2025
- Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias
Blood · 2024
- Pharmacological targeting of the cancer epigenome
Nature Cancer · 2024
- Inherent genome instability underlies trisomy 21-associated myeloid malignancies
Leukemia · 2024
- Dynamic joint stiffness in individuals with femoroacetabular impingement syndrome pre- and post-hip arthroscopy
Clinical Biomechanics · 2024
- CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Nature · 2023
- Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of <i>KMT2A</i>-r and <i>NPM1c</i> AML
Blood · 2023
- Females with hip-related pain demonstrate reduced kinetics at the hip and ankle during terminal stance of gait
Gait & Posture · 2023
- Data from YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis
2023
- Blood×5
- Clinical Biomechanics×4
- Gait & Posture×4
- Nature Chemical Biology×2
- Royal Society Open Science×2
- I‐Ju Yeh
Biochemistry, Genetics and Molecular Biology · Indiana University
- Clark D. Wells
Biochemistry, Genetics and Molecular Biology · Indiana University
- Emily M. King
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Aktan Alpsoy
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Jacob J. Adler
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile